NO327259B1 - Substituerte 2-benzylamino-2-fenyl-acetamid-forbindelser, farmasoytisk sammensetning som inneholder slike, samt anvendelse derav - Google Patents
Substituerte 2-benzylamino-2-fenyl-acetamid-forbindelser, farmasoytisk sammensetning som inneholder slike, samt anvendelse derav Download PDFInfo
- Publication number
- NO327259B1 NO327259B1 NO20003398A NO20003398A NO327259B1 NO 327259 B1 NO327259 B1 NO 327259B1 NO 20003398 A NO20003398 A NO 20003398A NO 20003398 A NO20003398 A NO 20003398A NO 327259 B1 NO327259 B1 NO 327259B1
- Authority
- NO
- Norway
- Prior art keywords
- benzylamino
- compound
- phenylacetamide
- hydrogen
- acetamide
- Prior art date
Links
- 239000008194 pharmaceutical composition Chemical class 0.000 title claims description 6
- PYVTTZQYAVUMNV-UHFFFAOYSA-N 2-(benzylamino)-2-phenylacetamide Chemical class C=1C=CC=CC=1C(C(=O)N)NCC1=CC=CC=C1 PYVTTZQYAVUMNV-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 19
- 239000001257 hydrogen Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000002193 Pain Diseases 0.000 claims abstract description 13
- 208000004296 neuralgia Diseases 0.000 claims abstract description 12
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 8
- 150000002367 halogens Chemical class 0.000 claims abstract description 8
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 7
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000003287 optical effect Effects 0.000 claims description 3
- SUAPKJRANCSCBZ-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC=C(F)C=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 SUAPKJRANCSCBZ-UHFFFAOYSA-N 0.000 claims description 2
- RBPLIQLNWOKJFW-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 RBPLIQLNWOKJFW-UHFFFAOYSA-N 0.000 claims description 2
- KWMDBCXQGPZBCB-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1F KWMDBCXQGPZBCB-UHFFFAOYSA-N 0.000 claims description 2
- OYHKKKNZSGIJNQ-UHFFFAOYSA-N 2-[[4-[(3-bromophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Br)=C1 OYHKKKNZSGIJNQ-UHFFFAOYSA-N 0.000 claims description 2
- MODFUWXCNUBNKW-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-(3-fluorophenyl)acetamide Chemical compound C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 MODFUWXCNUBNKW-UHFFFAOYSA-N 0.000 claims description 2
- UGAZPYAMTAVKDF-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 UGAZPYAMTAVKDF-UHFFFAOYSA-N 0.000 claims description 2
- HCSMEIBTXUDXFF-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 HCSMEIBTXUDXFF-UHFFFAOYSA-N 0.000 claims description 2
- AROJRYZKACVPEC-UHFFFAOYSA-N 2-phenyl-2-[(4-phenylmethoxyphenyl)methylamino]acetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1 AROJRYZKACVPEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 239000003195 sodium channel blocking agent Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000036407 pain Effects 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HCSMEIBTXUDXFF-OAQYLSRUSA-N (2r)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide Chemical compound N([C@@H](C(=O)N)C=1C=CC=CC=1)CC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 HCSMEIBTXUDXFF-OAQYLSRUSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000002485 Adiposis dolorosa Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000542 thalamic effect Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DWGCLOWZLAUWOW-OAQYLSRUSA-N (2R)-2-[[4-(3-fluorophenoxy)phenyl]methyl-methylamino]-2-phenylacetamide Chemical compound CN([C@@H](C(N)=O)C=1C=CC=CC=1)CC(C=C1)=CC=C1OC1=CC=CC(F)=C1 DWGCLOWZLAUWOW-OAQYLSRUSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LSWZNADCLYSACD-OAQYLSRUSA-N (2r)-2-[2-(4-phenoxyphenyl)ethylamino]-2-phenylacetamide Chemical compound N([C@@H](C(=O)N)C=1C=CC=CC=1)CCC(C=C1)=CC=C1OC1=CC=CC=C1 LSWZNADCLYSACD-OAQYLSRUSA-N 0.000 description 1
- JKFAEIFBEVWBEF-OAQYLSRUSA-N (2r)-2-[2-[4-(3-bromophenoxy)phenyl]ethylamino]-2-phenylacetamide Chemical compound N([C@@H](C(=O)N)C=1C=CC=CC=1)CCC(C=C1)=CC=C1OC1=CC=CC(Br)=C1 JKFAEIFBEVWBEF-OAQYLSRUSA-N 0.000 description 1
- NJIACDRMAROREE-OAQYLSRUSA-N (2r)-2-[2-[4-(3-chlorophenoxy)phenyl]ethylamino]-2-phenylacetamide Chemical compound N([C@@H](C(=O)N)C=1C=CC=CC=1)CCC(C=C1)=CC=C1OC1=CC=CC(Cl)=C1 NJIACDRMAROREE-OAQYLSRUSA-N 0.000 description 1
- GGSBKZGNRYOCDC-JOCHJYFZSA-N (2r)-2-[3-[4-(3-fluorophenoxy)phenyl]propylamino]-2-phenylacetamide Chemical compound N([C@@H](C(=O)N)C=1C=CC=CC=1)CCCC(C=C1)=CC=C1OC1=CC=CC(F)=C1 GGSBKZGNRYOCDC-JOCHJYFZSA-N 0.000 description 1
- IJWZITPGEAQOEI-HXUWFJFHSA-N (2r)-2-[[4-(3-fluorophenoxy)phenyl]methylamino]-2-phenylacetamide Chemical compound N([C@@H](C(=O)N)C=1C=CC=CC=1)CC(C=C1)=CC=C1OC1=CC=CC(F)=C1 IJWZITPGEAQOEI-HXUWFJFHSA-N 0.000 description 1
- CEQQFSJOOAPHEY-HSZRJFAPSA-N (2r)-2-[cyclopropyl-[[4-(3-fluorophenoxy)phenyl]methyl]amino]-2-phenylacetamide Chemical compound C1CC1N([C@@H](C(=O)N)C=1C=CC=CC=1)CC(C=C1)=CC=C1OC1=CC=CC(F)=C1 CEQQFSJOOAPHEY-HSZRJFAPSA-N 0.000 description 1
- KIYRSYYOVDHSPG-SSDOTTSWSA-N (2r)-2-amino-2-phenylacetamide Chemical compound NC(=O)[C@H](N)C1=CC=CC=C1 KIYRSYYOVDHSPG-SSDOTTSWSA-N 0.000 description 1
- LXOAFHGMXCFTOU-OGFXRTJISA-N (2r)-2-amino-2-phenylacetamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](N)C1=CC=CC=C1 LXOAFHGMXCFTOU-OGFXRTJISA-N 0.000 description 1
- LSWZNADCLYSACD-NRFANRHFSA-N (2s)-2-[2-(4-phenoxyphenyl)ethylamino]-2-phenylacetamide Chemical compound N([C@H](C(=O)N)C=1C=CC=CC=1)CCC(C=C1)=CC=C1OC1=CC=CC=C1 LSWZNADCLYSACD-NRFANRHFSA-N 0.000 description 1
- SZHAXJIUSCFQCN-NRFANRHFSA-N (2s)-2-[2-[4-(3-fluorophenoxy)phenyl]ethylamino]-2-phenylacetamide Chemical compound N([C@H](C(=O)N)C=1C=CC=CC=1)CCC(C=C1)=CC=C1OC1=CC=CC(F)=C1 SZHAXJIUSCFQCN-NRFANRHFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LRELHQBXMPLRIZ-UHFFFAOYSA-N 2-(2-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC=C(F)C=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 LRELHQBXMPLRIZ-UHFFFAOYSA-N 0.000 description 1
- NFQTVRAHHZHQOD-UHFFFAOYSA-N 2-(3-fluorophenyl)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]acetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 NFQTVRAHHZHQOD-UHFFFAOYSA-N 0.000 description 1
- UOQLROHUDITUCV-UHFFFAOYSA-N 2-[[4-[(3-bromophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Br)=C1 UOQLROHUDITUCV-UHFFFAOYSA-N 0.000 description 1
- DKNAWFODBVZCNG-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-(3-fluorophenyl)acetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC(F)=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 DKNAWFODBVZCNG-UHFFFAOYSA-N 0.000 description 1
- FPRBRZYZHYVNIN-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]-2-phenylacetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC(Cl)=C1 FPRBRZYZHYVNIN-UHFFFAOYSA-N 0.000 description 1
- ZQOSDNLYRQJWAX-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methylamino]phenyl]methylamino]-2-phenylacetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1NCC1=CC=CC(F)=C1 ZQOSDNLYRQJWAX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DNKSIIHRKWTIRH-UHFFFAOYSA-N 4-[(3-fluorophenyl)methoxy]benzaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(C=O)=CC=2)=C1 DNKSIIHRKWTIRH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DTHMTBUWTGVEFG-QRPNPIFTSA-N [(1s)-2-methoxy-2-oxo-1-phenylethyl]azanium;chloride Chemical compound Cl.COC(=O)[C@@H](N)C1=CC=CC=C1 DTHMTBUWTGVEFG-QRPNPIFTSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BVTUZIUTMWHSKN-UHFFFAOYSA-N methanesulfonic acid;2-phenyl-2-[(4-phenylmethoxyphenyl)methylamino]acetamide Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(C(=O)N)NCC(C=C1)=CC=C1OCC1=CC=CC=C1 BVTUZIUTMWHSKN-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9727521.8A GB9727521D0 (en) | 1997-12-31 | 1997-12-31 | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| PCT/EP1998/008158 WO1999035123A1 (fr) | 1997-12-31 | 1998-12-12 | Composes 2-benzylamino-2-phenyl-acetamide substitues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20003398D0 NO20003398D0 (no) | 2000-06-29 |
| NO20003398L NO20003398L (no) | 2000-08-02 |
| NO327259B1 true NO327259B1 (no) | 2009-05-25 |
Family
ID=10824340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20003398A NO327259B1 (no) | 1997-12-31 | 2000-06-29 | Substituerte 2-benzylamino-2-fenyl-acetamid-forbindelser, farmasoytisk sammensetning som inneholder slike, samt anvendelse derav |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6303819B1 (fr) |
| EP (1) | EP1044186B9 (fr) |
| JP (1) | JP3839665B2 (fr) |
| KR (1) | KR100629628B1 (fr) |
| AT (1) | ATE319680T1 (fr) |
| BG (1) | BG64700B1 (fr) |
| CA (1) | CA2316082C (fr) |
| CZ (1) | CZ296722B6 (fr) |
| DE (1) | DE69833797T2 (fr) |
| EA (1) | EA003097B1 (fr) |
| ES (1) | ES2256976T3 (fr) |
| GB (1) | GB9727521D0 (fr) |
| HK (1) | HK1028021A1 (fr) |
| HR (1) | HRP20000508B9 (fr) |
| HU (1) | HUP0100184A3 (fr) |
| ID (1) | ID26622A (fr) |
| IL (1) | IL136735A0 (fr) |
| NO (1) | NO327259B1 (fr) |
| NZ (1) | NZ505441A (fr) |
| PL (1) | PL194745B1 (fr) |
| PT (1) | PT1044186E (fr) |
| TR (1) | TR200001950T2 (fr) |
| WO (1) | WO1999035123A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| JP2004517840A (ja) * | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
| US8084447B2 (en) | 2001-09-03 | 2011-12-27 | Newron Pharmaceuticals S.P.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use |
| US6667327B2 (en) | 2002-02-04 | 2003-12-23 | Hoffmann-La Roche Inc. | Pyridine amido derivatives |
| EP1438956A1 (fr) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Dérivés alpha-aminoamides en tant qu'agents antimigraine |
| WO2004087125A1 (fr) * | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Derives d'acides amines en tant qu'inhibiteurs des canaux sodiques de mammiferes |
| EP1524267A1 (fr) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Heterocycles benzyleaminoalkylene substitues |
| KR100856141B1 (ko) | 2003-10-23 | 2008-09-03 | 에프. 호프만-라 로슈 아게 | 모노아민 산화효소 ｂ 저해제로서의 벤즈아제핀 유도체 |
| EP1533298A1 (fr) * | 2003-11-21 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | Dérivés de 3-aminopyrrolidone |
| EP1533302A1 (fr) * | 2003-11-21 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | Dérivés de l'histidine |
| EP1535908A1 (fr) | 2003-11-24 | 2005-06-01 | Newron Pharmaceuticals S.p.A. | Derives de N-acyl-N-benzylalkylendiamine |
| EP1588704A1 (fr) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie |
| KR101277520B1 (ko) * | 2004-09-10 | 2013-06-21 | 뉴론 파마슈티칼즈 에스. 피. 에이. | （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 |
| RU2397160C9 (ru) | 2005-12-22 | 2012-10-27 | НЬЮРОН ФАРМАСЬЮТИКАЛЗ С.п.А. | 2-фенилэтиламинопроизводные в качестве модуляторов кальциевых и/или натриевых каналов |
| EP1870097A1 (fr) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Dérivés d'alpha-aminoamide pour le traitement de troubles cognitifs |
| AU2008223916A1 (en) * | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
| US11111208B2 (en) * | 2019-06-17 | 2021-09-07 | RK Pharma Solutions LLC | Process for the preparation of safinamide mesylate intermediate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541204A (en) * | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| KR0147963B1 (ko) * | 1995-01-10 | 1998-08-17 | 강박광 | 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법 |
| US5688830A (en) * | 1996-01-25 | 1997-11-18 | Syntex (U.S.A.) Inc. | Treatment of neuropathic pain |
-
1997
- 1997-12-31 GB GBGB9727521.8A patent/GB9727521D0/en not_active Ceased
-
1998
- 1998-12-12 ES ES98964511T patent/ES2256976T3/es not_active Expired - Lifetime
- 1998-12-12 PT PT98964511T patent/PT1044186E/pt unknown
- 1998-12-12 KR KR1020007007306A patent/KR100629628B1/ko not_active IP Right Cessation
- 1998-12-12 CZ CZ20002496A patent/CZ296722B6/cs not_active IP Right Cessation
- 1998-12-12 EP EP98964511A patent/EP1044186B9/fr not_active Expired - Lifetime
- 1998-12-12 ID IDW20001444A patent/ID26622A/id unknown
- 1998-12-12 HU HU0100184A patent/HUP0100184A3/hu unknown
- 1998-12-12 JP JP2000527525A patent/JP3839665B2/ja not_active Expired - Fee Related
- 1998-12-12 CA CA002316082A patent/CA2316082C/fr not_active Expired - Fee Related
- 1998-12-12 DE DE69833797T patent/DE69833797T2/de not_active Expired - Fee Related
- 1998-12-12 AT AT98964511T patent/ATE319680T1/de not_active IP Right Cessation
- 1998-12-12 PL PL98341514A patent/PL194745B1/pl not_active IP Right Cessation
- 1998-12-12 TR TR2000/01950T patent/TR200001950T2/xx unknown
- 1998-12-12 WO PCT/EP1998/008158 patent/WO1999035123A1/fr active IP Right Grant
- 1998-12-12 EA EA200000728A patent/EA003097B1/ru not_active IP Right Cessation
- 1998-12-12 IL IL13673598A patent/IL136735A0/xx not_active IP Right Cessation
- 1998-12-12 NZ NZ505441A patent/NZ505441A/en unknown
- 1998-12-12 US US09/581,254 patent/US6303819B1/en not_active Expired - Fee Related
-
2000
- 2000-06-28 BG BG104569A patent/BG64700B1/bg unknown
- 2000-06-29 NO NO20003398A patent/NO327259B1/no not_active IP Right Cessation
- 2000-07-27 HR HR20000508A patent/HRP20000508B9/xx not_active IP Right Cessation
- 2000-11-20 HK HK00107399A patent/HK1028021A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327259B1 (no) | Substituerte 2-benzylamino-2-fenyl-acetamid-forbindelser, farmasoytisk sammensetning som inneholder slike, samt anvendelse derav | |
| KR100525587B1 (ko) | 알파-아미노아미드 유도체 및 이를 포함하는 진통제용 약제학적 조성물 | |
| JP4040089B2 (ja) | ２−（４−置換）−ベンジルアミノ−２−メチル−プロパンアミド誘導体 | |
| MXPA98000718A (en) | Derivatives of 2- (4-substitute) -bencilamino-2-methyl-propanam | |
| US5446066A (en) | Substituted (arylalkoxybenzyl)aminopropanamide derivatives and process for their preparation | |
| US5912242A (en) | N-(4-substituted-benzyl)-2-aminolactam derivatives | |
| HUT70944A (en) | Substituted (arylalkylaminobenzyl)-aminopropionamide derivatives, their preparation and pharmaceutical compns. contg. them with anti-epileptic, neuroprotective and antidepressant activity | |
| US6815443B2 (en) | 5-Amino-1-pentene-3-ol substituted derivatives | |
| MXPA00006354A (en) | Substituted 2-benzylamino-2-phenyl-acetamide compounds | |
| MXPA00006352A (en) | Alpha-aminoamide derivatives useful as analgesic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |